Clinical Collaboration

Five months into pandemic, Israel expected to appoint coronavirus czar - Haaretz | 7/21/2020

Netanyahu Pours Billions to Douse Coronavirus Flames. It May Not Be Enough He was the director of Ichilov Hospital in Tel Aviv from 1993 to 2015, except for a three-year hiatus when he served as Health Ministry director-general. Since leaving Ichilov, he has headed a private firm that manages patient treatment by providing a variety of experts, as well as a scientific-clinical collaboration project at the Weizmann …

Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma | Yahoo News | 7/20/2020

CONTACT-03 is the third of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who progressed during or following treatment with an immune checkpoint inhibitor as the …

Follow Clinical Collaboration:    

Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 | Business Wire | 7/17/2020

… shareholders, Nanobiotix made organizational adjustments to control costs while priorities regarding clinical development remained unchanged. Nanobiotix also announced that the protocol for the phase I clinical trial for NBTXR3 in pancreatic cancer under its clinical collaboration with The University of Texas MD Anderson Cancer Center has been allowed to proceed by the US Food and Drug Administration (FDA). At ASCO 2020, Nanobiotix announced positive new data from the expansion part …

Oncorus Announces Clinical Trial Collaboration with Merck to Evaluate the Combination of Oncorus’ ONCR-177 with Merck’s KEYTRUDA® (pembrolizumab)… | Malvern Daily Record | 7/16/2020

… ONCR-177, Oncorus’ lead product candidate, is an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy being developed for the treatment of multiple solid tumor indications. “We are pleased to enter into this clinical collaboration with Merck, as we believe the mechanisms of ONCR-177 and KEYTRUDA are highly complementary,” said Theodore (Ted) A. Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. “KEYTRUDA blocks the interaction between …

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab | Business Wire | 7/16/2020

… allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta ® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration . For more information, visit www.humanigen.com . About Catalent Biologics Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug …

Immunomedics Extends Deal With Roche for Two New Studies - July 14, 2020 - Zacks.com | 7/14/2020

Immunomedics Inc. ( IMMU - Free Report ) announced that it will extend its clinical collaboration with Roche ( RHHBY - Free Report ) with two new studies evaluating the combination of anti-Trop-2 antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) of the former and the latter’s Tecentriq (atezolizumab) in patients with metastatic urothelial cancer (mUC) and metastatic non-small cell lung cancer (mNSCLC). Tecentriq is Roche’s programmed cell death ligand 1 (PD-L1 …

Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers | Globe Newswire | 7/13/2020

… PLAINS, N.J., July 13, 2020 (GLOBE NEWSWIRE) – Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced an extension of its current clinical collaboration with Roche to evaluate Trodelvy, Immunomedics’ anti-Trop-2 ADC, in combination with Tecentriq, Roche’s programmed cell death ligand 1 (PD-L1)-blocking checkpoint inhibitor (CPI), in patients with metastatic urothelial cancer (mUC) and …

Immunomedics Expands Collaboration with Roche Evaluating TrodelvyTM | 7/13/2020

… have ongoing collaboration in first-line metastatic Immunomedics also announces Phase 2 NeoSTAR study in neoadjuvant has begun patient enrollment Morris Plains, N.J., July 13, conjugates (ADC), today announced an extension of its current clinical collaboration with Roche to evaluate Trodelvy, Immunomedics’ anti-Trop-2 ADC, in combination with Tecentriq, Roche’s programmed cell death ligand 1 (PD-L1)-blocking checkpoint inhibitor (CPI), in patients with metastatic urothelial cancer (mUC) cancer …

Frost & Sullivan Recognizes DrFirst for Solutions Providing Secure Communication, Collaboration, and Real-Time Access to Patient Information at the Point of Care | 7/9/2020

… Award for its suite of products that improve healthcare providers’ clinical view of patients’ medical information and drug regimens SANTA CLARA, Calif. — July 9, 2020— Providers across multiple care settings require technology that supports clinical collaboration (including telehealth), medication and clinical management, medication reconciliation, and medication adherence. After an extensive review of the U.S. digital health data market, Frost & Sullivan recognizes DrFirst for its range of technology solutions that address …

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody | Globe Newswire | 7/8/2020

… nivolumab (Opdivo®) in patients with non-small cell lung cancer, and in combination with nivolumab in addition to standard of care chemotherapy in patients with pancreatic cancer. The trial will be conducted under a clinical collaboration agreement with Bristol-Myers Squibb (BMS) Company, and is expected to begin in the second half of 2020. “We are very pleased with this new addition to our patent coverage in the EU, which …

$KTOV Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody - OTC Dynamics | 7/8/2020

… nivolumab (Opdivo®) in patients with non-small cell lung cancer, and in combination with nivolumab in addition to standard of care chemotherapy in patients with pancreatic cancer. The trial will be conducted under a clinical collaboration agreement with Bristol-Myers Squibb (BMS) Company, and is expected to begin in the second half of 2020. “We are very pleased with this new addition to our patent coverage in the EU, which …

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody Nasdaq:KTOV | Globe Newswire | 7/8/2020

… nivolumab (Opdivo®) in patients with non-small cell lung cancer, and in combination with nivolumab in addition to standard of care chemotherapy in patients with pancreatic cancer. The trial will be conducted under a clinical collaboration agreement with Bristol-Myers Squibb (BMS) Company, and is expected to begin in the second half of 2020. “We are very pleased with this new addition to our patent coverage in the EU, which …

Humanigen Appoints Senior Executives to Management Team | Business Wire | 7/7/2020

… allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration . For more information, visit www.humanigen.com Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that …

Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors | PR Newswire | 7/6/2020

SUZHOU, China , and ROCKVILLE, Md. , July 6, Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the combination of APG-115, Ascentage’s MDM2-p53 inhibitor, and KEYTRUDA ® (pembrolizumab), MSD’s anti-PD-1 therapy, for the treatment of patients with advanced solid tumors. Under the agreement, Ascentage will sponsor …

Ascentage, Merck To Evaluate APG-115 In Combination With KEYTRUDA In Advanced Solid Tumors | Markets Insider | Business Insider | 7/6/2020

RTTNews) - Ascentage Pharma said that it reached a clinical collaboration with Merck & Co (MRK) to evaluate the combination of APG-115, Ascentage’s MDM2-p53 inhibitor, and KEYTRUDA or pembrolizumab, Merck’s anti-PD-1 therapy, for the treatment of patients with advanced solid tumors. As per the deal, Ascentage will sponsor an open-label, multicenter, phase Ib/II study (NCT03611868) is designed to evaluate the safety and efficacy of APG-115 …

Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors | Business & Finance | heraldchronicle.com | PR Newswire | 7/6/2020

SUZHOU, China, and ROCKVILLE, Md., July 6, 2020 /PRNewswire/ – Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the combination of APG-115, Ascentage’s MDM2-p53 inhibitor, and KEYTRUDA®(pembrolizumab), MSD’s anti-PD-1 therapy, for the treatment of patients with advanced solid tumors. Under the agreement, Ascentage …

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer | 7/3/2020

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How! • Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib; • Participation will provide Ipsen access to the respective study results to support potential future regulatory submissions in its territories. Ipsen, toda “Ipsen has built its strength …

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer | Business Wire | 7/2/2020

PARIS- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials. CONTACT-01 is evaluating the safety and efficacy of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with …

Webinar: Clinical Collaboration in the Time of COVID-19 | 7/2/2020

Join Us for a Webinar on Clinical Collaboration in the Time of COVID-19 . Thursday, 02 July 2020 16:00 – 18:00 Objective: To share the experiences of the Western Cape response to COVID-19 in an effort to support the responses of other provinces. To build synergies and coherence of approach in the public and private sector to ensure equity in patient care. Chair: Coenie Koegelenberg Hosts: Glenda Gray and Lydia …

Virtual clinical collaboration in the COVID-19 era - The Link by Proximie - Medium | 7/2/2020

Empowering cardiologists across continents to share expertise that helped to save a life. Proximie Follow Jul 2 · 3 min read U sing Proximie , Professor Fadi Sawaya, MD, FACC, Director of the Structural Heart and Valve Program at the American University of Beirut Medical Center , was able to remotely collaborate with an expert cardiologist in Copenhagen, and several Abbott Medical device experts in the US, during a critical transcatheter aortic valve …

Ipsen, Exelixis, Roche team for combo study in lung, prostate cancer | 7/2/2020

Ipsen ( OTCPK:IPSEY ) will join the Exelixis (NASDAQ: EXEL ) and Roche ( OTCQX:RHHBY ) clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III trials. CONTACT-01 is evaluating the safety and efficacy of Exelixis’ cabozantinib (cabometyx) in combination with Roche’s atezolizumab (tecentriq) in patients with metastatic non-small cell lung cancer. CONTACT-02 is evaluating the safety and efficacy of cabozantinib …

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer | Financial Buzz | 7/2/2020

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials. CONTACT-01 is evaluating the safety and efficacy of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an …

First Patient Infused in Joint Humanigen/Kite, A Gilead Company Clinical Study | Malvern Daily Record | 6/30/2020

… ZUMA-19 study, which is being conducted in collaboration with Kite, A Gilead Company. Details of the ZUMA-19 study can be found at www.clinicaltrials.gov/ct2/show/NCT04314843 . “We are excited to see this clinical collaboration move forward as we seek to understand the potential benefit of lenzilumab being administered with CAR T therapy in patients with relapsed or refractory large B-cell lymphoma,” said Cameron Durrant, MD, chief executive …

Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer | BioSpace | 6/30/2020

… June 30, 2020 12:00 UTC – Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial – – CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – ALAMEDA, Calif.–( BUSINESS WIRE )– Exelixis, Inc. . (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with …

NA Proactive news snapshot: Humanigen, 1933 Industries, HighGold Mining, Heritage Cannabis … | 6/30/2020

… relapsed or refractory Large B-cell Lymphoma. This so-called ZUMA-19 study is being conducted in collaboration with Kite, which is a Gilead Sciences ( NASDAQ:GILD ) company. “We are excited to see this clinical collaboration move forward as we seek to understand the potential benefit of lenzilumab being administered with CAR T therapy in patients with relapsed or refractory large B-cell lymphoma,” Cameron Durrant, the chief executive officer …

Food and Drug Administration

Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 | Business Wire | 7/17/2020

clinical collaboration with The University of Texas MD Anderson Cancer Center has been allowed to proceed by the US Food and Drug Administration (FDA). At ASCO 2020, Nanobiotix announced positive new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy …

National Cancer Institute

Humanigen Appoints Senior Executives to Management Team | Business Wire | 7/7/2020

… MD, MBA, Chief Executive Officer, Humanigen. Dr. Chappell began his career as a Howard Hughes Medical Institute fellow at the National Cancer Institute where he studied tumor immunology and published in the field of T … with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment …

COVID-19

COVID-19: First Data Confirm Neurologic Symptoms Common | WebMD | 4/17/2020

COVID-19: First Data Confirm Neurologic Symptoms Common What your doctor is reading on Medscape.com: APRIL 16, 2020 – COVID-19 is strongly associated with neurologic manifestations, including acute cerebrovascular diseases, impaired consciousness, and skeletal muscle … of China, and the Major Refractory Diseases Pilot Project of Clinical Collaboration With Chinese and Western Medicine. The investigators and Stevens have reported no relevant financial relationships. Josephson has reported receiving personal fees from JAMA …

Home Health

HHCN Poll: 24% of Home Health Agencies Have Laid Off Therapy Staff Post-PDGM | Home Health Care News | 4/14/2020

… appear to be a substantial drop in overall therapy utilization, according to the survey. About one-third of the surveyed home health professionals said their organization’s therapy utilization has decreased by at least 15% since … avoiding therapy services entirely, Bayada has aimed to foster more clinical collaboration, giving PTs, OTs and SLPs more chances to work alongside nurses in “clinical huddles.” The goal of the huddles: to make sure each …

Clinical Research

Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma | PR Newswire | 1/13/2020

… reference their respective Investigational New Drug applications and will work collaboratively to obtain necessary regulatory and institutional approvals. In this clinical collaboration, Actinium will provide drug product, support for its administration and certain trial costs … for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation …

Patient Engagement

QliqSOFT Announces Healthcare Chatbot that Solves Patient Engagement, Instantly. | Business Wire | 1/9/2020

… intents and dialogue flows or customize Quincy to build chatbots to suit your unique needs. (Graphic: Business Wire) Qliqsoft’s conversational patient engagement platform provides patients care-related information via mobile texting and web-based messaging … architecture, QliqSOFT’s Secure Texting, On-Call Scheduling, Patient Communication, and Clinical Collaboration solutions are trusted by over 1,000 Hospitals, Home Health, and Hospice Organizations to deliver HIPAA-compliant, reliable, and real-time communication between doctors …

Feinberg School of Medicine

Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer | Globe Newswire | 1/9/2020

… Institute, University of Colorado and University of Vermont, where he headed Human Medical Genetics. He is an alumnus of the Feinberg School of Medicine at Northwestern University, the Institute of Materials Research and Innovation, University … small cell lung cancer (NSCLC). Kitov has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE: BMY ) for the planned Phase 1/2 clinical trials to evaluate the combination of CM-24 with the …

Biotech

Portage Announces Filing of Financial Statements and Accompanying MD&A and Provides Company Operations Updates | PR Newswire | 12/31/2019

… presentation of Phase I/II data, and entry into a research collaboration with Merck – TORONTO , Dec. 31, 2019 /PRNewswire/ - Portage Biotech Inc., (“Portage” or the “Company”) (Canadian Securities Exchange: PBT.U, OTC Markets: PTGEF ) is very … in June, Portage announced that Intensity Therapeutics entered into a clinical collaboration with Merck to evaluate INT230-6, Intensity’s investigational treatment for refractory solid tumors, in combination with KEYTRUDA ® (pembrolizumab). Further clinical updates was presented at …

American Society of Clinical Oncology

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

CAR-T

Humanigen Terminates Exploration of Potential Rights Offering - GuruFocus.com | 12/2/2019

… December 2, 2019 / Humanigen, Inc., ( OTCQB: HGEN ) (“Humanigen”), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other cell therapies, announced today that it is has terminated the process … GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the sequential use of lenzilumab with Yescarta ® , axicabtagene ciloleucel, in a multicenter clinical …

Electronic Medical Record

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

… 4300 in the South Hall. Each pavilion showcases solutions that address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care … link it to core clinical and business applications such as electronic medical records (EMR) and enterprise resource planning (ERP) systems. Hyland Healthcare is the only technology partner that offers a full suite of content services …

EMR

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

… 4300 in the South Hall. Each pavilion showcases solutions that address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care … core clinical and business applications such as electronic medical records (EMR) and enterprise resource planning (ERP) systems. Hyland Healthcare is the only technology partner that offers a full suite of content services and enterprise imaging …

PACS

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

… medical images across the entire enterprise while enhancing the radiologist’s expanded role in value-driven care. Significant product enhancements include: PACSgear Video Touch 4K , a new addition to Hyland Healthcare’s PACSgear MDR-Video Touch family … address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care image integration. Chris Magyar , senior manager of product management for …

Enterprise Imaging

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

CHICAGO , Dec. 1, Hyland Healthcare , a leading global provider of content services and enterprise imaging, is unveiling a host of new products and updates at the Radiological Society of North America (RSNA) annual meeting in … address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care image integration. Chris Magyar , senior manager of product management for …

Medical Imaging

Hyland Healthcare Shares Imaging Trends Ahead of RSNA 2019 | PR Newswire | 11/26/2019

… of imaging strategies . Hyland Healthcare’s cloud-neutral stance provides customers with configurable options for hosting some or all of their medical imaging in the cloud, which can alleviate the growing costs of on premise solutions … in the South Hall, features seven pavilions covering workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care image integration. For more information, visit HylandHealthcare.com and booth 4300 …

Medical Education

Global $1.66Bn Cognitive Collaboration Market Outlook to 2024 | PR Newswire | 11/26/2019

Clinical Collaboration and Medical Education Driving the Adoption of Cognitive Collaboration Solutions in the Healthcare Vertical 10.7 Retail 10.7.1 Growing Need to Offer Custom-Based Services to Customers Driving the Adoption of Cognitive Collaboration Solutions in the Retail Vertical 10.8 Others 11 Cognitive Collaboration Market By Region 11.1 Introduction 11.2 North America 11.2.1 United States 11.2.1.1 Rapid Growth of Technologies and Infrastructures to Boost the Adoption of AI-Based Collaboration …

Genomics

Cofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling CenterCofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling Center | 11/26/2019

Cofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling Center Boston, MA – September 26, 2019 – Today Cofactor Genomics announced that it has expanded the leadership team with the promotion of Natalie LaFranzo, PhD to Vice President of Market Development. Dr. LaFranzo’s amplified leadership role includes clinical collaboration management, corporate partnerships, and strategic marketing. Dr. LaFranzo has been with Cofactor most recently for three years, with previous roles …

Clinical Data

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress | The Wapakoneta Daily News | 11/22/2019

… Zymeworks and its collaborator BeiGene, Ltd. plan to advance ZW25 into potentially registration-enabling global studies in HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA), based on these durable and consistent clinical data. “The promising ZW25 data at ESMO Asia further build momentum for the expanding footprint of our ZW25 clinical development program with BeiGene,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks. “Cancer is a global …

Diagnostic Imaging

Fujifilm Presents Comprehensive Enterprise Imaging Portfolio At RSNA 2019 | PR Newswire | 11/21/2019

… U.S.A. , Inc. “That calls for an enterprise imaging strategy that is capable of merging platforms, augmenting siloed systems, and empowering clinical collaboration; allowing providers to see the whole patient, so they can treat the whole … FUJIFILM Medical Systems U.S.A. , Inc. is a leading provider of diagnostic imaging products and medical informatics solutions that meet the evolving needs of healthcare facilities both today and tomorrow. From an unrivaled selection of digital …

Digital Health

ARTIDIS Joins the TMC Accelerator Device Cohort to Ensure That Its Cancer Diagnostic and Therapeutic Optimization Innovation Gains Early Access to the US Market | PR Newswire | 11/18/2019

… best place to take patient care to the next level. It also enables us to further strengthen ongoing scientific and clinical collaborations focusing on breast, lung and pancreatic cancer with our colleagues from three major … complex health care issues of today and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu . About ARTIDIS AG ARTIDIS AG is a spinoff from the Biozentrum, University of …

Clinical Operations

Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer | 11/12/2019

… Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer Published: Nov 12, 2019 Investigator-sponsored study being conducted in clinical collaboration with Aravive and AstraZeneca HOUSTON and WILMINGTON, Del., Nov. 12, 2019 (GLOBE NEWSWIRE … ovarian cancer,” said Laura Bonifacio, Pharm.D., Ph.D., vice president of clinical operations at Aravive. About Ovarian Cancer Each year in the United States, more than 22,000 women develop ovarian cancer and there are approximately 14,240 …

NIH

Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results | PR Newswire | 11/12/2019

clinical collaboration agreement (ClinicalTrials.gov Identifier: NCT03835533). DNA-encoded monoclonal antibodies (dMAb ® )/DNA-encoded Bi-specific T Cell Engagers (dBTE) Inovio and its collaborator, The Wistar Institute, received a $4.6 million grant from the National Institutes of Health (NIH) in support of innovative research of antimicrobial resistance (AMR) and continued development of Inovio’s DNA-encoded monoclonal antibodies (dMAb ® ) platform. Using direct local delivery into the body by the CELLECTRA ® platform, the …

Radiotherapy

NANOBIOTIX Announces New Results From Pre-Clinical Immuno-Oncology Study at SITC 2019 | Malvern Daily Record | 11/12/2019

clinical collaboration 1 with The University of Texas MD Anderson Cancer Center . The research, which evaluated first-in-class radioenhancer NBTXR3 activated by radiation therapy in combination with anti-PD-1 and anti-CTLA-4 immune checkpoint inhibitors, was presented last week at the 2019 Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Combination of a radiation-enhancing nanoparticle, radiotherapy, and immune checkpoint inhibitors for treating metastasized lung …

HIPAA

Caregility Helps Philips, Department of Veterans Affairs, Veterans of Foreign Wars and The American Legion Bring Local Telehealth Services to Rural Veterans | PR Newswire | 11/11/2019

EATONTOWN, N.J. Caregility , a clinical collaboration and communications company changing the point of care, today announced the company’s involvement in the ATLAS pilot project, an initiative to bring virtual care offerings from the Department of … technology and equipment donated by Philips and Caregility combined with HIPAA-trained attendants provided by CareLink, the pods improve access to care for veterans in underserved areas where there are limited healthcare providers. “Telehealth is …

Virtual Care

Caregility Helps Philips, Department of Veterans Affairs, Veterans of Foreign Wars and The American Legion Bring Local Telehealth Services to Rural Veterans | PR Newswire | 11/11/2019

EATONTOWN, N.J. Caregility , a clinical collaboration and communications company changing the point of care, today announced the company’s involvement in the ATLAS pilot project, an initiative to bring virtual care offerings from the Department of Veterans Affairs (VA) to veterans in targeted rural areas. Caregility-Project-Atlas-Ribbon-Cutting ATLAS, which stands for Accessing Telehealth through Local Area Stations, is a collaboration between the VA, Veterans of Foreign Wars (VFW …

Bristol-Myers

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody | Globe Newswire | 7/8/2020

clinical collaboration agreement with Bristol-Myers Squibb (BMS) Company, and is expected to begin in the second half of 2020. “We are very pleased with this new addition to our patent coverage in the EU, which, together with the corresponding US patent which has been granted earlier this year, strongly positions CM24 as a unique approach for treating cancer patients. We look forward to the anticipated initiation of our planned …

Novartis

Humanigen Appoints Senior Executives to Management Team | Business Wire | 7/7/2020

… Emerging Markets, covering 42 countries in the Middle East, West Asia and Africa Region. He also held leadership positons at Novartis and at Roche Pharmaceuticals. “We are pleased that both Dr. Chappell and Mr. Tousley … with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment …

Merck

Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors | PR Newswire | 7/6/2020

… global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the combination of APG-115, Ascentage’s MDM2-p53 inhibitor … with advanced solid tumors.” KEYTRUDA ® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ , USA. About APG-115 APG-115 is an orally administered, selective, small-molecule …

Merck & Co

Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors | PR Newswire | 7/6/2020

… global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the combination of APG-115, Ascentage’s MDM2-p53 inhibitor … registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ , USA. About APG-115 APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. APG …

Genentech

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer | Business Wire | 7/2/2020

PARIS- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase … in its territory. Tecentriq ® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. About CONTACT-01 CONTACT-01 is a global, multicenter, randomized, Phase III, open-label study that aims to …

Gilead

First Patient Infused in Joint Humanigen/Kite, A Gilead Company Clinical Study | Business & Finance | heraldchronicle.com | Business Wire | 6/30/2020

Gilead Company. Details of the ZUMA-19 study can be found at www.clinicaltrials.gov/ct2/show/NCT04314843 . “We are excited to see this clinical collaboration move forward as we seek to understand the potential benefit of lenzilumab being administered with CAR T therapy in patients with relapsed or refractory large B-cell lymphoma,” said Cameron Durrant, MD, chief executive officer of Humanigen. About Humanigen, Inc. Humanigen, Inc. is developing its portfolio …

Encompass Health

HHCN Poll: 24% of Home Health Agencies Have Laid Off Therapy Staff Post-PDGM | Home Health Care News | 4/14/2020

… avoided knee-jerk therapy reactions because of PDGM. Instead of avoiding therapy services entirely, Bayada has aimed to foster more clinical collaboration, giving PTs, OTs and SLPs more chances to work alongside nurses in “clinical … our visit approach. Any of that,” April Anthony, CEO of Encompass Health’s (NYSE: EHC) home health and hospice segment, previously told HHCN . “We really feel like the whole therapy-behavior change is over-cooked.” While …

Caregility

Caregility Announces New Features in HIPAA Compliant iConsult Mobile App to help in fight against COVID-19 | PR Newswire | 4/1/2020

EATONTOWN, N.J. Caregility , a clinical collaboration and communications company focused on providing secure, reliable two-way audio and video communications for any device and clinical workflow, in both inpatient and outpatient settings, announces it has developed new features to address the challenges of using iPads and Smart Tablets with remote monitoring solutions in patient rooms. The new features enable secure remote calling into the room without the need for a …

Pfizer

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 | Globe Newswire | 3/18/2020

… for patients with desmoid tumors and as a combination therapy for patients with multiple myeloma. The ‘087 patent, assigned to Pfizer, Inc., expires in 2039. The ‘087 patent is a composition of matter patent that … in multiple myeloma. To date, SpringWorks has entered into two clinical collaborations to evaluate nirogacestat in combination with GlaxoSmithKline’s BCMA antibody-drug conjugate belantamab mafodotin and with Allogene’s allogeneic BCMA CAR-T cell therapy ALLO …

GlaxoSmithKline

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 | Globe Newswire | 3/18/2020

… clinical collaborations to evaluate nirogacestat in combination with GlaxoSmithKline’s BCMA antibody-drug conjugate belantamab mafodotin and with Allogene’s allogeneic BCMA CAR-T cell therapy ALLO-715. About Nirogacestat Nirogacestat is an investigational, oral, selective, small molecule gamma-secretase inhibitor in Phase 3 clinical development for desmoid tumors, which are rare and often debilitating and disfiguring soft-tissue tumors. Gamma secretase cleaves multiple transmembrane protein complexes, including Notch, which is believed …

Biogen

Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer | Globe Newswire | 1/9/2020

… our team. Furthermore, Dr. Liang’s prior leadership experience across all phases of clinical development at leading large biopharmaceutical companies, including Biogen, IDEC and Amgen, will be invaluable to Kitov’s clinical development plans.” Dr. Liang previously … small cell lung cancer (NSCLC). Kitov has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE: BMY ) for the planned Phase 1/2 clinical trials to evaluate the combination of CM-24 with the …

Bristol-Myers Squibb

Kitov Pharma Announces Closing of FameWave Acquisition | Markets Insider | 1/8/2020

… inhibitor, CM-24 Kitov intends to initiate a phase 1b/2a clinical trial of CM-24 + nivolumab in collaboration with Bristol-Myers Squibb in the second half of 2020 TEL AVIV, Israel, Jan. 08, 2020 … small cell lung cancer (NSCLC). Kitov has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE:BMY) for the planned Phase 1/2 clinical trials to evaluate the combination of CM-24 with the …

Amarin

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals | 12/19/2019

… analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amarin ( AMRN - Free Report ) , Amgen ( AMGN - Free Report ) , Gilead Sciences, Inc. ( GILD - Free Report ) , Biogen … NASH. Earlier, Gilead’s Kite and Kiniksa Pharmaceuticals, Ltd. entered a clinical collaboration to conduct a phase II, multicenter study on pipeline candidate mavrilimumab in combination with CAR T-cell therapy Yescarta. The objective of the …

Amgen

Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More - December 18, 2019 - Zacks.com | 12/18/2019

… pipeline and regulatory updates this week. While Amarin ( AMRN - Free Report ) gained on a label expansion for its key drug, Amgen ( AMGN - Free Report ) won approval for its osteoporosis drug in Europe. Both Gilead Sciences … Kite and Kiniksa Pharmaceuticals, Ltd. ( KNSA - Free Report ) entered a clinical collaboration to conduct a phase II, multicenter study on pipeline candidate mavrilimumab in combination with CAR T-cell therapy Yescarta. The objective of the …

Medtronic

ViewRay Announces Collaborations with Elekta and Medtronic | BioSpace | 12/3/2019

Medtronic (NYSE: MDT) to enter into a clinical collaboration in an area of mutual interest that includes exploring the clinical benefits of the MRIdian MR-guided radiation therapy system. In connection with the collaboration, Medtronic has committed to invest in a minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement. ViewRay’s largest shareholder, Fosun International Limited (“Fosun”), has also committed capital up to …

MRIdian

ViewRay Announces Collaborations with Elekta and Medtronic | BioSpace | 12/3/2019

clinical collaboration in an area of mutual interest that includes exploring the clinical benefits of the MRIdian MR-guided radiation therapy system. In connection with the collaboration, Medtronic has committed to invest in a minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement. ViewRay’s largest shareholder, Fosun International Limited (“Fosun”), has also committed capital up to an amount that would enable it to …

Seattle Genetics

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

Weather AP Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer 1 hr ago Save BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Dec 2, 2019– Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the …

Hyland Healthcare

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

CHICAGO , Dec. 1, Hyland Healthcare , a leading global provider of content services and enterprise imaging, is unveiling a host of new products and updates at the Radiological Society of North America (RSNA) annual meeting in … address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care image integration. Chris Magyar , senior manager of product management for …

BeiGene

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress | The Wapakoneta Daily News | 11/22/2019

… mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore. Zymeworks and its collaborator BeiGene, Ltd. plan to advance ZW25 into potentially registration-enabling global studies in HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA), based on these durable and consistent clinical data. “The promising ZW25 data at ESMO …

Compugen

EuroBiotech: More Articles of Note | FierceBiotech | 11/14/2019

Compugen posted initial phase 1 data on its anti-PVRIG antibody. The trial detected early signs of efficacy in microsatellite stable colorectal cancer. Statement Lytix Biopharma formed a clinical collaboration with Iovance Biotherapeutics . The companies will test Lytix’s oncolytic peptide in combination with Iovance’s T cell therapy. Release SUBSCRIBE NOW Poxel said FDA feedback supports its plan to use the 505(b)(2) pathway to file for approval in nonalcoholic …

Iovance Biotherapeutics

EuroBiotech: More Articles of Note | FierceBiotech | 11/14/2019

clinical collaboration with Iovance Biotherapeutics . The companies will test Lytix’s oncolytic peptide in combination with Iovance’s T cell therapy. Release SUBSCRIBE NOW Poxel said FDA feedback supports its plan to use the 505(b)(2) pathway to file for approval in nonalcoholic steatohepatitis. The French biotech plans to rely on Actos data in its filing. Statement Lunac Therapeutics spun out of the University of Leeds with £2.7 million ($3.5 million …

Regeneron Pharmaceuticals

Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results | PR Newswire | 11/12/2019

… and INO-9012, an immune activator encoding IL-12, in combination with Libtayo ® , a PD-1 blocking antibody produced by Regeneron Pharmaceuticals in collaboration with Sanofi. Key interim data from the 52-patient clinical trial … Cancer Research Institute (CRI), as part of Inovio’s previously established clinical collaboration agreement (ClinicalTrials.gov Identifier: NCT03835533). DNA-encoded monoclonal antibodies (dMAb ® )/DNA-encoded Bi-specific T Cell Engagers (dBTE) Inovio and its collaborator, The Wistar …

Clovis Oncology

Clovis Oncology (CLVS) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… 2019 , 8:30 a.m. ET Contents: Prepared Remarks: Operator Ladies and gentlemen, thank you for standing by, and welcome to the Clovis Oncology third-quarter 2019 earnings conference call. [Operator instructions] I would now like to … compound FAP-2286. We remain very enthusiastic about our ongoing clinical collaboration with Bristol-Myers Squibb, and I’ll take a moment to review our combination studies for both Rubraca and lucitanib with nivolumab. I’ll begin …

Immunomedics

Clovis Oncology (CLVS) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… for both Rubraca and lucitanib, and then discuss our newest compound FAP-2286. We remain very enthusiastic about our ongoing clinical collaboration with Bristol-Myers Squibb, and I’ll take a moment to review our combination … portion of the study; and also Rubraca in combination with Immunomedics’ sacituzumab govitecan for the treatment of advanced metastatic triple-negative breast cancer, relapsed platinum-resistant ovarian cancer and metastatic urothelial cancers, which is currently …

AbbVie

Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results | BioSpace | 11/7/2019

clinical collaboration with AbbVie.” Milano continued, “Overall, our team is executing on a high level and we are well positioned to continue to accelerate our activity through the end of this year and, importantly, into 2020.” ILLUMINATE (tilsotolimod) Clinical Development ILLUMINATE 301 – Randomized phase 3 trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory metastatic melanoma: Approximately 90 sites active in 11 …

William Blair

Aileron Therapeutics, Inc. (ALRN) CEO Manuel Aivado on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/10/2019

… Aivado - President & Chief Executive Officer Vojislav Vukovic - Chief Medical Officer Allen Annis - Head of Research Conference Call Participants Rob Andrew - William Blair Justin Zelin - Canaccord Jacques Villefranc - LifeSci Capital Operator Ladies and gentlemen, thank you … move forward in liposarcoma, I know you mentioned there’s a clinical collaboration there with Pfizer. Are there any plans for kind of partnership in that program particularly given that combination with Ibrance? Thanks very much …

Agenus Inc. (AGEN) CEO Dr. Garo Armen on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/4/2019

… CEO Anna Wijatyk - Head, Clinical Development and Operations Christine Klaskin - VP, Finance Conference Call Participants Biren Amin - Jefferies Matt Phipps - William Blair Harshita Polishetty - B. Riley FBR Inc. Operator Good day, ladies and gentlemen. And … development as well as for some of the collaborative – in clinical collaborations that we’re contemplating. And so, what you will see is that the accrual will be open. And to our discretion, we’ve completed our …

Merrill Lynch

Clovis Oncology (CLVS) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… for both Rubraca and lucitanib, and then discuss our newest compound FAP-2286. We remain very enthusiastic about our ongoing clinical collaboration with Bristol-Myers Squibb, and I’ll take a moment to review our combination … of America. Please go ahead. Tazeen Ahmad – Bank of America Merrill Lynch – Analyst Hi, good morning. Thanks for taking my questions. Pat, just your view about the European market. We’ve talked now for a while …

Gilead Sciences, Inc. (GILD) CEO Daniel O’Day on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/3/2019

… Brian Abrahams - RBC Capital Markets Geoffrey Porges - SVB Leerink Michael Yee - Jeffries Carter Gould - UBS Ying Huang - Bank of America Merrill Lynch Umer Raffat - Evercore Phil Nadeau - Cowen and Company Cory Kasimov - JPMorgan Ronny Gal … few weeks ago we announced our intent to enter into clinical collaboration with Novo Nordisk to evaluate the utility of combining their approved GLP-1 drug semaglutide with both our FXR agonists cilofexor and our …

SunTrust Robinson Humphrey

Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/2/2019

… Yaron Werber – Cowen Michael Schmidt – Guggenheim Silvan Tuerkcan – Oppenheimer Justin Burns – RBC Capital Markets Ted Tenthoff – Piper Jaffray Peter Lawson – SunTrust Robinson Humphrey George Farmer – BMO Capital Markets Stephen Willey – Stifel Paul Choi – Goldman Sachs … our combination trials of cabozantinib with immune checkpoint inhibitor. Our clinical collaboration with BMS combining cabozantinib with nivolumab alone for cabozantinib with nivolumab and ipilimumab is making great progress. The ongoing Phase III CheckMate 9ER …

Exelixis Inc (EXEL) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/2/2019

… cabozantinib development program and will start with an overview of our combination trials of cabozantinib with immune checkpoint inhibitors. Our clinical collaboration with BMS, combining cabozantinib with nivolumab alone or cabozantinib with nivolumab and ipilimumab … Thank you. Our next question is from Peter Lawson from SunTrust Robinson Humphrey. Your line is now open. Peter Lawson – SunTrust Robinson Humphrey – Analyst Hi. Thanks for taking my question. Just if I may have …

RBC Capital Markets

Encompass Health Corporation (EHC) CEO Mark Tarr on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 4/26/2019

… Home Health and Hospice Conference Call Participants Matt Larew - William Blair Brian Tanquilut - Jefferies AJ Rice - Credit Suisse Frank Morgan - RBC Capital Markets Joanna Gajuk - Bank of America Dana Hanley - Stephens Kevin Ellich - Craig Hallum … this transaction in June. We continue to make progress on clinical collaborations and achieved a 36% clinical collaboration rate in the first quarter of 2019, a 250 basis point increase over the first quarter of …

Incyte (INCY) Q3 2017 Results - Earnings Call Transcript | Seeking Alpha | 10/31/2017

… Eric Schmidt - Cowen & Co. LLC Salveen Richter - Goldman Sachs & Co. LLC Ying Huang - Bank of America Merrill Lynch Brian Abrahams - RBC Capital Markets LLC Alethia Young - Credit Suisse Securities (NYSE: USA ) LLC M. Ian Somaiya … that we have agreed with AstraZeneca to expand our existing clinical collaboration and move into Phase 3 development in a trial which will study epacadostat plus durvalumab in patients with non-small cell lung cancer …

University of Texas MD Anderson Cancer Center

Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 | Business Wire | 7/17/2020

clinical collaboration with The University of Texas MD Anderson Cancer Center has been allowed to proceed by the US Food and Drug Administration (FDA). At ASCO 2020, Nanobiotix announced positive new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy …

MD Anderson Cancer Center

Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 | Business Wire | 7/17/2020

clinical collaboration with The University of Texas MD Anderson Cancer Center has been allowed to proceed by the US Food and Drug Administration (FDA). At ASCO 2020, Nanobiotix announced positive new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy …

Mayo Clinic

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab | Business Wire | 7/16/2020

… is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s lead therapeutic candidate. Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients … with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com . About Catalent Biologics Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological …

Medical Center

Virtual clinical collaboration in the COVID-19 era - The Link by Proximie - Medium | 7/2/2020

Empowering cardiologists across continents to share expertise that helped to save a life. Proximie Follow Jul 2 · 3 min read U sing Proximie , Professor Fadi Sawaya, MD, FACC, Director of the Structural Heart and Valve Program at the American University of Beirut Medical Center , was able to remotely collaborate with an expert cardiologist in Copenhagen, and several Abbott Medical device experts in the US, during a critical transcatheter aortic valve …

The University of Texas MD Anderson Cancer Center

CarThera and KIYATEC Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Cancer | Business Wire | 11/18/2019

… GREENVILLE, S.C. & PARIS–(BUSINESS WIRE)–Nov 18, 2019– KIYATEC, Inc. and CarThera announce today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with … experts, John de Groot, M.D., professor and chairman ad interim, The University of Texas MD Anderson Cancer Center, who recognized the synergistic nature of their respective clinical initiatives. CarThera is currently conducting a multi-center …

Novant Health

Walgreens Inks Retail Health Collaboration Deal With Novant - October 8, 2019 - Zacks.com | 10/8/2019

Recently, Walgreens Boots Alliance ( WBA - Free Report ) signed a retail health clinical collaboration and services deal as well as a retail pharmacy-oriented transaction with Novant Health. Per the agreement, Walgreens will acquire nine of Novant Health’s retail pharmacies. Novant Health, a leading healthcare provider with 15 medical centers across more than 640 locations, specializes in offering innovative medical treatments. This collaboration is in line with Walgreen’s commitment toward offering …

Memorial Sloan Kettering Cancer Center

Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast Cancer | Business Wire | 10/7/2019

… Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing treatments for hormone driven cancers, today announced a Phase 2 clinical collaboration with the Wisconsin Oncology Network. This clinical collaboration will evaluate whether the addition … SOLTI and a first line (1L) biochemical recurrence study at Memorial Sloan Kettering Cancer Center, will provide clinicians with a complete picture of how Apristor works in advanced ER+,PR+,HER2- breast cancer and inform …

Harvard Medical School

Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel | Globe Newswire | 7/11/2019

… Therapeutics. In that role, she was responsible for all partnering activities, including most recently leading negotiations for their broad-based clinical collaborations with Bristol Meyers Squibb on NKTR-214. Dr. Decker also executed multiple additional … University School of Medicine and conducted her postdoctoral training at Harvard Medical School. General Counsel As General Counsel, Ms. Phillips will lead Atreca’s legal, compliance and intellectual property functions. She is a seasoned attorney with …

Massachusetts General Hospital

Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology | Benzinga | 5/20/2019

… treatment options for these patients. We hope this study will help us identify a new treatment paradigm.” Dr Brastianos is also an Assistant Physician in Medicine in the Department of Hematology/Oncology at Massachusetts General Hospital. Her research interests focus on metastatic brain cancer, and she has been extensively published in this field. Dr Brastianos will be joined on the study Steering Committee by distinguished expert clinicians from leading centres …

NYU Langone Health

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy | 11/29/2017

… focused on melanoma and cancers of the bladder, head and neck, and kidneys Emerging data supports expansion of collaboration with NYU Langone Health and its Perlmutter Cancer Center into melanoma and cancers of the bladder … the gut microbiota modulate immunotherapeutic responses. “Data from our ongoing clinical collaborations in melanoma show that gut bacteria signatures could help determine if a cancer immunotherapy will work,” said Bruce Roberts, Ph.D., Chief Scientific Officer …

Perlmutter Cancer Center

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy | 11/29/2017

… of the bladder, head and neck, and kidneys Emerging data supports expansion of collaboration with NYU Langone Health and its Perlmutter Cancer Center into melanoma and cancers of the bladder and lung Biosciences , an affiliate … the gut microbiota modulate immunotherapeutic responses. “Data from our ongoing clinical collaborations in melanoma show that gut bacteria signatures could help determine if a cancer immunotherapy will work,” said Bruce Roberts, Ph.D., Chief Scientific Officer …

Mount Sinai Health System

Bronx-Lebanon Hospital Center and Fit4D Secure Robin Hood Foundation Grant to Offer Diabetes Management Program | PRWeb | 11/28/2017

clinical collaboration with the Mount Sinai Health System, as well as 15 accredited residency and fellowship programs, are further indicators of its medical excellence. About Fit4D Fit4D’s mission is to improve the lives of people living with diabetes. Fit4D delivers effective patient programs through an optimized mix of humans and technology to deliver measurable outcomes in an affordable manner. The Fit4D clinical team of Certified Diabetes Educators (CDEs) is comprised …

Sinai Health System

Bronx-Lebanon Hospital Center and Fit4D Secure Robin Hood Foundation Grant to Offer Diabetes Management Program | PRWeb | 11/28/2017

clinical collaboration with the Mount Sinai Health System, as well as 15 accredited residency and fellowship programs, are further indicators of its medical excellence. About Fit4D Fit4D’s mission is to improve the lives of people living with diabetes. Fit4D delivers effective patient programs through an optimized mix of humans and technology to deliver measurable outcomes in an affordable manner. The Fit4D clinical team of Certified Diabetes Educators (CDEs) is comprised …

Brooklyn Hospital Center, Brooklyn NY

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn | PR Newswire | 11/20/2017

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn Collaboration will ensure access to timely, convenient and lifesaving cardiac care News provided by 12:53 ET Share this article BROOKLYN, N.Y. , Nov. 20, 2017 /PRNewswire/ – The Brooklyn Hospital Center (TBHC) and Mount Sinai Heart hosted a breakfast reception on November 16 , to celebrate a clinical collaboration that provides access to comprehensive cardiac care …

Mount Sinai Hospital

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn | PR Newswire | 11/20/2017

… PRNewswire/ – The Brooklyn Hospital Center (TBHC) and Mount Sinai Heart hosted a breakfast reception on November 16 , to celebrate a clinical collaboration that provides access to comprehensive cardiac care in Downtown Brooklyn . The alliance makes … Sharma, MD , Director of Clinical and Interventional Cardiology at The Mount Sinai Hospital. “ Mount Sinai has a 19-year track record of offering the highest level of patient safety in New York State , and we …

New York Eye and Ear Infirmary, New York NY

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn | PR Newswire | 11/20/2017

… PRNewswire/ – The Brooklyn Hospital Center (TBHC) and Mount Sinai Heart hosted a breakfast reception on November 16 , to celebrate a clinical collaboration that provides access to comprehensive cardiac care in Downtown Brooklyn . The alliance makes … of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai …

Mount Sinai Beth Israel

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn | PR Newswire | 11/20/2017

… PRNewswire/ – The Brooklyn Hospital Center (TBHC) and Mount Sinai Heart hosted a breakfast reception on November 16 , to celebrate a clinical collaboration that provides access to comprehensive cardiac care in Downtown Brooklyn . The alliance makes … for Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit http://www.mountsinai.org/ , or find Mount Sinai …

St Joseph Health

Agfa HealthCare Enterprise Imaging Platform Enters Southwestern Ontario Market | PR Newswire | 11/13/2017

… and the region, consolidating multiple imaging IT systems. “We are delighted these hospitals in the southwest region of Ontario have selected our Enterprise Imaging solutions. This will consolidate patient data and help facilitate clinical collaboration and continuity across the care continuum,” says Frank Pecaitis , senior vice president, North America , Sales and Marketing, Agfa HealthCare. The suite of Enterprise Imaging solutions includes the following applications: Enterprise Imaging for Radiology - a highly …

HealthSouth

HealthSouth Reports Results for Third Quarter 2017 and Updates Full-Year 2017 Guidance | CNBC | 10/27/2017

BIRMINGHAM, Ala., Oct. 26, 2017 /PRNewswire/ – HealthSouth Corporation (NYSE: HLS), one of the nation’s largest providers of post-acute healthcare services, offering both facility-based and home-based patient care, today reported its results of … associated with the Company’s rebranding and name change and TeamWorks clinical collaboration initiative. During the third quarter of 2017, the Company invested $1.5 million in its rebranding and name change and $2.3 million in its …

Aetna

(USA-VA-Chantilly) Clinical Collaboration Nurs | 5/15/2019

Aetna Clinical Collaboration Nurs in Chantilly , Virginia Req ID: 60138BR Full time telework position open to candidates in VA, WV, PA, OH. 10-25% travel is involved. The Provider Collaboration Clinician is responsible for a defined population in the assigned provider group(s). The clinician will use practice-wide data to identify clinical trends and opportunities for improvement and will partner with practice leadersh Job Function: Health Care Aetna is an …

(USA-WV-Charleston) Clinical Collaboration Nurs | 5/15/2019

Aetna Clinical Collaboration Nurs in Charleston , West Virginia Req ID: 60138BR Full time telework position open to candidates in VA, WV, PA, OH. 10-25% travel is involved. The Provider Collaboration Clinician is responsible for a defined population in the assigned provider group(s). The clinician will use practice-wide data to identify clinical trends and opportunities for improvement and will partner with practice leadersh Job Function: Health Care Aetna is …

Gisela Schwab

Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma | Yahoo News | 7/20/2020

CONTACT-03 is the third of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 … inhibitor-based regimens move to earlier lines of therapy,” said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “More data are needed to better understand the sequential use of …

Behzad Aghazadeh

Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers | Globe Newswire | 7/13/2020

… Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced an extension of its current clinical collaboration with Roche to evaluate Trodelvy, Immunomedics’ anti-Trop-2 ADC, in combination with … with Roche, a global leader in cancer therapy,” commented Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics. “We believe these combination studies will build a strong foundation for early-line cancer treatment developments.” Separately, Immunomedics also …

April Anthony

HHCN Poll: 24% of Home Health Agencies Have Laid Off Therapy Staff Post-PDGM | Home Health Care News | 4/14/2020

… avoided knee-jerk therapy reactions because of PDGM. Instead of avoiding therapy services entirely, Bayada has aimed to foster more clinical collaboration, giving PTs, OTs and SLPs more chances to work alongside nurses in “clinical … compensation to our therapy, our visit approach. Any of that,” April Anthony, CEO of Encompass Health’s (NYSE: EHC) home health and hospice segment, previously told HHCN . “We really feel like the whole therapy-behavior change …

Saqib Islam

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 | Globe Newswire | 3/18/2020

… issued this patent, which builds upon our existing intellectual property portfolio and extends patent protection for nirogacestat to 2039,” said Saqib Islam, Chief Executive Officer of SpringWorks. “The granting of this patent represents an important … in multiple myeloma. To date, SpringWorks has entered into two clinical collaborations to evaluate nirogacestat in combination with GlaxoSmithKline’s BCMA antibody-drug conjugate belantamab mafodotin and with Allogene’s allogeneic BCMA CAR-T cell therapy ALLO …

Ali Tehrani

Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities | BioSpace | 1/13/2020

… a chemotherapy-free treatment option to people with advanced HER2-positive, hormone receptor-positive breast cancer. Zymeworks entered into a clinical collaboration with Pfizer to advance the study. ZW25 achieved two additional regulatory milestones, recently … spectrum of HER2-expressing cancers and lines of therapy,” said Ali Tehrani, Ph.D., President and CEO at Zymeworks. “As our second therapeutic candidate, ZW49, continues to advance in the clinic, we are excited about its …

David Chang

Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma | Globe Newswire | 1/13/2020

… believe allogeneic CAR T therapy is the next frontier in genetically engineered cell therapy for the treatment of cancer,” said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene Therapeutics. “The search to … with industry leaders. To date, SpringWorks has entered into two clinical collaborations to evaluate nirogacestat in combination with GlaxoSmithKline’s BCMA antibody-drug conjugate belantamab mafodotin and with Allogene’s allogeneic BCMA CAR-T cell therapy ALLO …

Kenji Yasukawa

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

Weather AP Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer 1 hr ago Save BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Dec 2, 2019– Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the …

Andrew Krivoshik

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through … with other agents in different stages of urothelial cancer,” said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head at Astellas. “We look forward to further evaluating enfortumab vedotin and pembrolizumab in …

Roger Dansey

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through … with previously untreated locally advanced or metastatic urothelial cancer,” said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. “Recent data from a phase 1b trial of enfortumab vedotin in combination with pembrolizumab showed evidence …

Howard W. Robin

Nektar Therapeutics (NKTR) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/7/2019

… Nektars website at nektar.com. With that, I will hand the call over to our President and CEO, Howard Robin, Howard? Howard W. Robin – President and CEO Thank you, Jennifer. Good afternoon everyone and thank you … utilize the ADCC Mechanism. As you know we had a preclinical collaboration in place with Janssen for NKTR-255 and they are currently evaluating the agent in combination with several different therapies in their oncology …

Jonathan Zalevsky

Nektar Therapeutics (NKTR) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/7/2019

… joining us today. With us are Howard Robin, our President and CEO; Gil Labrucherie our COO and CFO; and Dr. Jonathan Zalevsky our Head of R&D.On todays call, we expect to make forward-looking … utilize the ADCC Mechanism. As you know we had a preclinical collaboration in place with Janssen for NKTR-255 and they are currently evaluating the agent in combination with several different therapies in their oncology …

Tamar Howson

MEI Pharma Reports First Quarter Fiscal Year 2020 Results and Operational Highlights | PR Newswire | 11/7/2019

… primary focus remained on advancing the clinical development of ME-401, as well as voruciclib, while continuing to explore additional clinical collaborations and partnering opportunities to effectively leverage the potential of our drug candidates for … and 7.4 months (range 2.6-14.7 months), respectively. In July 2019 , Tamar Howson , M.S., MBA, a highly experienced business development executive with over 30 years of service in the pharmaceutical and biotechnology industry, joined the Board …

Charles M. Baum

Mirati Therapeutics Reports Third Quarter 2019 Fin | 11/5/2019

… 34 th Annual Meeting on November 9, 2019 . Announced on July 9, 2019 that the Company had entered into a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati’s investigational KRAS G12C … with Novartis, will significantly increase the eligible patient population,» said Charles M. Baum , M.D., Ph.D., President and Chief Executive Officer at Mirati. «We continue to expand and accelerate our KRAS programs and expect to continue …

Steve Hoffman

TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results | Globe Newswire | 11/4/2019

… SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer TYME Initiates Pre-Clinical Collaboration with NYU Langone to Advance SM-88 Data NEW YORK, Nov. 04, 2019 … improved safety profiles for patients with metastatic cancers,” said Mr. Steve Hoffman, Chairman and Chief Executive Officer of TYME. “We are excited to enter into the next stage of growth for TYME and its stakeholders …

Fred Hutchinson

Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230 | PR Newswire | 10/21/2019

DUBLIN , Oct. 21, Alkermes plc (Nasdaq: ALKS ) today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center ( Fred Hutch ) for ALKS 4230, Alkermes’ immuno-oncology drug candidate. ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex …

Doug Coltharp

Encompass Health Looks to Improve Clinical Collaboration Rate, Expects $45M PDGM Headwind | Home Health Care News | 9/5/2019

… both in-patient rehabilitation hospitals (IRFs) and home health agencies is also actively looking to improve upon its in-house clinical collaboration rate. “A key part of our strategy is to integrate our service lines … million before 2020 even begins, Executive Vice President and CFO Doug Coltharp said Wednesday, also speaking at the Baird conference. Nonetheless, leadership is confident in the company’s ability to eventually overcome initial disruptions — and recent …

Fouad Namouni

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer | PR Newswire | 7/18/2019

… Myers Squibb Company (NYSE: BMY ) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga ® (regorafenib) and Bristol … with cancers typically not responsive to I-O therapy,” said Fouad Namouni, M.D., head of development, oncology, Bristol-Myers Squibb. “We are looking forward to a strong collaboration to investigate nivolumab with regorafenib, with the …

Scott Z. Fields

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer | PR Newswire | 7/18/2019

… Myers Squibb Company (NYSE: BMY ) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga ® (regorafenib) and Bristol … hope to deliver an additional therapeutic benefit to patients,” said Scott Z. Fields , M.D., senior vice president and head of Oncology Development at Bayer’s Pharmaceuticals Division. “We continue to invest in innovative approaches to maximize …

John McHutchison

Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Business & Finance | manchestertimes.com | Business Wire | 5/31/2019

Spring Has Sprung Photo AP Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma May 31, 2019 Save SANTA MONICA … relapsed or refractory large B-cell lymphoma is treated,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead. “As leaders in cell therapy, we are committed to pursuing a number …

Mark Chao

Forty Seven’s (FTSV) CEO Mark McCamish on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/14/2019

… Hannah Deresiewicz – Stern Investor Relations Mark McCamish – Chief Executive Officer Chris Takimoto – Chief Medical Officer Ann Rhoads – Chief Financial Officer Mark Chao – Founder and Vice President of Clinical Development Conference Call Participants Matthew Harrison – Morgan … recent month, we were excited to enter into two new clinical collaboration, one with Genentech and one was Acerta, which allows us to evaluate 5F9 and Rituximab, as part of the triplet regimen, each with …

Michael Schmidt

Forty Seven’s (FTSV) CEO Mark McCamish on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/14/2019

… Mark Chao – Founder and Vice President of Clinical Development Conference Call Participants Matthew Harrison – Morgan Stanley Martin Auster – Credit Suisse Michael Schmidt – Guggenheim Arlinda Lee – Canaccord Mark Breidenbach – Oppenheimer Robert Hazlett – BTIG Operator Good day … recent month, we were excited to enter into two new clinical collaboration, one with Genentech and one was Acerta, which allows us to evaluate 5F9 and Rituximab, as part of the triplet regimen, each with …

Robert Forrester

Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/13/2019

… afternoon to discuss Verastem Oncology’s financial results and corporate highlights for the first quarter of 2019. I’m joined today by Robert Forrester, our President and Chief Executive Officer; Joe Lobacki, our Chief Commercial Officer; Dan … inhibitor defactinib, which is currently being evaluated in four separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types including pancreatic, non-small cell lung, ovarian and mesothelioma and …

Robert Forrest

Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/13/2019

… afternoon to discuss Verastem Oncology’s financial results and corporate highlights for the first quarter of 2019. I’m joined today by Robert Forrester, our President and Chief Executive Officer; Joe Lobacki, our Chief Commercial Officer; Dan … inhibitor defactinib, which is currently being evaluated in four separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types including pancreatic, non-small cell lung, ovarian and mesothelioma and …

Joseph Lobacki

Verastem, Inc. (VSTM) CEO Robert Forrester on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/10/2019

… Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants John Doyle - VP, IR Robert Forrester - President, CEO & Director Joseph Lobacki - EVP & Chief Commercial Officer Daniel Paterson - COO Robert Gagnon - CFO Conference Call Participants … inhibitor, defactinib, which is currently being evaluated in 4 separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, non-small cell lung, ovarian and mesothelioma. And …

Mike Morris

Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/2/2019

… Conference Call May 1, 2019 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President-Public Affairs and Investor Relations Mike Morrissey – President and Chief Executive Officer Chris Senner – Chief Financial Officer P.J. Haley – Senior … our combination trials of cabozantinib with immune checkpoint inhibitor. Our clinical collaboration with BMS combining cabozantinib with nivolumab alone for cabozantinib with nivolumab and ipilimumab is making great progress. The ongoing Phase III CheckMate 9ER …

Cleveland, Ohio

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients | 5/30/2020

clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide immunogen targeting survivin, a cell-survival protein present in glioblastoma and many other cancers. (PRNewsfoto/MimiVax, LLC) This is a Phase 2 study now open at the Cleveland Clinic, Cleveland OH . The goal is to establish safety and tolerability of the drug combination and assess clinical activity of SurVaxM with pembrolizumab in …

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients | Benzinga | 5/30/2020

BUFFALO, N.Y. , May 30, 2020 /PRNewswire/ – MimiVax LLC, a clinical-stage biotechnology company in Buffalo, N.Y. , USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide immunogen targeting survivin, a cell-survival protein present in glioblastoma and many other cancers. This is a Phase 2 study now open at the Cleveland Clinic …

Buffalo, New York

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients | 5/30/2020

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients News provided by May 30, 2020, 08:00 ET Share this article BUFFALO, N.Y. , May 30, 2020 /PRNewswire/ – MimiVax LLC, a clinical-stage biotechnology company in Buffalo, N.Y. , USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide …

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients | Benzinga | 5/30/2020

BUFFALO, N.Y. , May 30, 2020 /PRNewswire/ – MimiVax LLC, a clinical-stage biotechnology company in Buffalo, N.Y. , USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide immunogen targeting survivin, a cell-survival protein present in glioblastoma and many other cancers. This is a Phase 2 study now open at the Cleveland Clinic …